The Advisory Committee on Immunization Practices voted 13 to 2 to endorse the use of Pfizer's Prevnar 13 vaccine to protect people 65 and older from pneumococcal bacteria that can lead to infections such as pneumonia. However, the panel is worried that Medicare will not cover the vaccine for patients who were already treated with Merck's Pneumovax vaccine. Medicare would have to adjust its policies in order for such patients to be eligible for reimbursement, an official for the insurance program said.

Full Story:

Related Summaries